Narnatumab

Narnatumab
Monoclonal antibody
TypeWhole antibody
SourceMouse
TargetMST1R (aka RON)
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6454H10026N1754O2020S44
Molar mass145922.10 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Narnatumab is a human monoclonal antibody designed for the treatment of cancer.[1] Clinical development was abandoned after phase I trials.[2][3]

Narnatumab was developed by ImClone Systems.

References

[edit]
  1. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Narnatumab" (PDF). American Medical Association. Archived from the original (PDF) on 28 September 2012.
  2. ^ "Narnatumumab". AdisInsight. Springer Nature Switzerland AG. Retrieved 31 January 2017.
  3. ^ LoRusso PM, Gounder M, Jalal SI, André V, Kambhampati SR, Loizos N, et al. (August 2017). "Phase 1 study of narnatumab, an anti-RON receptor monoclonal antibody, in patients with advanced solid tumors". Investigational New Drugs. 35 (4): 442–450. doi:10.1007/s10637-016-0413-0. PMC 5502198. PMID 28161886.